Introduction
Over the last decades, the survival rate of children who receive haematopoietic SCT (HSCT) has considerably improved, resulting in a large population of childhood transplant survivors. The conditioning regimen (CR) given before HSCT may or may not be myeloablative. The choice of CR, especially in children, depends on the underlying disease (malignant or not), the age of the recipient, and pre-HSCT toxicity related to first-line treatment. Although the main aim of the HSCT procedure is to cure the underlying disease, an assessment of transplant-related side effects, such as early and late post-transplant toxicity should be carried out, especially in children. It is well known that conventional CR is the gold standard for malignant diseases, even if it is usually associated with early and long-term morbidity. The early and late complications can be the result of damage caused by chemotherapy and/or radiotherapy (RT) that are included in the CR. These complications may be related to individual predisposition to developing morbidities, pretransplant treatment-related toxicity, immunosuppressive therapies, and chronic GVHD (cGVHD). Polymorphism analysis evaluates the individual predisposition to toxicity and can predict those patients that are at risk of developing complications, and consequently it may help in designing tailored CRs and in identifying targets for therapeutic intervention. 1 Most published paediatric studies have analysed the early and late toxicity that occurs after HSCT, whereas only a few papers have reported the impact of pretransplant evaluation on outcome of children received HSCT.
The aim of this report is to define whether the assessment of children before HSCT may be helpful to identify patients at risk of developing early and late complications in order to individualize the CR, and to personalize the follow-up. The long life expectancy and the high cure rate are other reasons that suggest trying to reduce transplant-related toxicity.
Assessment of pretransplant-and post transplant-related complications
The pre-transplant and post-transplant features that should be taken into consideration include: primary diagnosis, type and dosage of treatments used during the first-line therapy, disease phase, recipient and donor gender, age at diagnosis and at HSCT, diagnosis-HSCT interval, donorrecipient pair HLA compatibility, CR (TBI vs chemotherapy), number of infused mononuclear cells, acute and cGVHD, and any major complications that may have occurred before or after HSCT. Table 1 shows the type and rate of the most frequent early and late toxicities that may occur after HSCT.
We herein analyse the individual organs that may be involved and we report the main risk factors that should be evaluated in the pre-HSCT assessment.
Risk features for cataract
Prolonged pre-transplant steroid therapy, as well as RT involving orbits and/or the skull, 31 especially if given at high doses, 32 predispose to cataract. TBI compared with BU and other chemotherapies, is the most frequent factor related to increased risk of cataract. 33 Long-term steroid treatment following transplant, as well as the occurrence of cGVHD can accelerate cataract development. 34 Van Kempen-Harteveld et al. 35 reported that shielding the eyes during TBI correlates with a decreased occurrence of cataract and an increased latency time, without increasing the risk of central nervous system relapses. This procedure should be recommended in patients at high risk of developing cataract. The minimal essential follow-up for children given HSCT include clinical ocular evaluation with slit-lamp examination, performed before HSCT, and yearly until the thirteenth year post transplant. It has been demonstrated that after this time the risk of cataract is significantly reduced.
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Risk features for cardiotoxicity Cardiotoxicity can present as acute or late onset and may be either subclinical and asymptomatic or progressive with clinical symptoms. Young age, female gender, total dose and administration rate of anthracycline treatment (4250-300 mg/m 2 ), 7 concomitant mantle RT and/or other medications, such as Cy, bleomycin, and other conditions affecting heart function 32,37 are the most frequent factors related to increased risk of cardiotoxicity. The cardiac muscle cells can be damaged, thus inducing left ventricular dysfunction (ejection fractiono55%; shortening fraction o30%), 38, 39 or more rarely, abnormalities of the electrical pathways that conduct impulses, or pericardial or blood vessel disease. 32 Patients who receive 200 mg/kg of CY, or TBI are considered at risk of left ventricular impairment. Recently, Uderzo et al. 7 reported that 19% of children receiving TBI had abnormal shortening fraction compared with 2% of children without TBI. Most children have subclinical cardiac abnormalities that rarely limit their quality of life. Possible approaches to preventing or minimizing cardiotoxicity may include adding cardioprotection to cardiotoxic chemotherapy 37 or liposomal anthracyclines that are less cardiotoxic. 40 Early detection of subclinical cardiotoxic effects involves carrying out echocardiograms that allow us to properly measure and monitor myocardial injury: ejection fraction and shortening fraction should be studied before and after cardiotoxic treatment. For patients with ejection fraction of less than 55% and shortening fraction of less than 30% an individually tailored, noncardiotoxic treatment should be administered, taking into consideration the underlying disease (malignant vs nonmalignant) and type of HSCT. Echocardiograms should be repeated annually, because both the severity and prevalence of cardiac abnormalities increase over time and because conditions, such as pregnancy, smoke, metabolic abnormalities and infections can worsen heart failure. 7 Risk factors for pulmonary toxicity Abnormalities of the pulmonary function test are frequently reported in children given HSCT. 2, 7, 41 Patients treated with bleomycin, carmustine, RT or surgery to the chest or lung are at risk of developing pulmonary failure after HSCT. Younger age, history of lung infections, asthma or other lung problems, 32 BU, melphalan (L-PAM), CY and methotrexate may increase pulmonary toxicity. High-dose and single-fraction TBI, is associated with restrictive pulmonary disease. 42 Chronic GVHD is the main risk factor implicated in reducing lung function in children. 7 Forced expiratory volume and forced vital capacity are the best tests to detect pulmonary abnormalities, both in symptomatic and in asymptomatic patients.
32, 43 Forced Leydig cell failure (7) 15
Germ cell failure (after TBI 99) 16 Delayed menarche (after TBI 44) 15 Overt ovarian failure (after TBI 90) 16 Growth impairment Liver VOD (4.6-41) [17] [18] [19] Viral hepatitis (14-50), 20 iron overload (52) expiratory volume and forced vital capacity levels of less than 85% before transplant can predict pulmonary failure, and patients with pulmonary function test abnormalities should be carefully followed up, especially if they develop cGVHD.
Patients who suffered from previous episodes of pneumonia, and in particular those with suspected or documented pulmonary fungal infections, should be evaluated before HSCT by lung computerized tomography (CT) and by the search for serum galactomannan antigen in the plasma. Unrelated donor HSCT, duration of primary antifungal therapy of less than 1 month, partial clinical response to an earlier invasive aspergillosis and incomplete resolution of imaging findings, 44 predispose to a relapse of invasive aspergillosis after HSCT. Surgical resection followed by administration of antifungal therapy might decrease the probability of relapse after HSCT in cases of residual aspergillosis lesion. 44, 45 Risk factors for thyroid toxicity Radio therapy involving the head, neck, and spine, and in particular high doses of radiation at a younger age (especially females) are risk factors related to thyroid problems. 32 Compensated hypothyroidism is the most frequent thyroid complication following TBI, with a frequency of 15 vs 2.1% of overt hypothyroidism. 14 Compensated elevations in thyroid-stimulating hormone have also been observed after BU/CY (11.7%). 46 Baseline evaluation of thyroid function, including thyroid-stimulating hormone and thyroxine (fT4) levels, should be performed before HSCT in all patients, and in particular in those treated with RT. Thyroid function testing should be repeated yearly, especially during periods of rapid growth.
32 Thyroid ultrasound should be performed before HSCT on patients treated with RT to investigate the possible presence of thyroid nodules or other parenchymal abnormalities.
Risk factors for gonad toxicity
Ovarian toxicity depends on the type and total dose of administered CT. The patient's age at the time of treatment plays an important role in ovarian failure, with an increased risk in older females. 47 Among the types of CT that can induce ovarian failure, alkylating agents, such as BU, carmustine, chlorambucil, CY, ifosfamide, L-PAM, procarbazine, and thiotepa (TT) can cause ovarian damage when given at high doses.
32 CY given at a dosage of 200 mg/Kg preserves ovarian function in 54% of females, 48 whereas BU is associated with ovarian failure in almost all cases. 16 TBI and RT delivered to the abdomen, pelvis and lower spine induce ovarian damage with degree of impairment related to dose, fractionated schedule and age at administration. 32 The irradiation dose that will induce permanent damage in 50% of human oocytes (LD 50 ) is of less than 2 Gy. 49 Females who receive TBI during premenarchal age are at a lower risk of developing early ovarian dysfunction. 2, 50 Although the probability of ovarian recovery after TBI ranges between 10 and 14%, no pregnancies have been reported following the use of BU/CY in patients with leukaemia. 51 Baseline female gonad function screening, including dosage of pituitary gonadotropins and sex steroid hormone secretion should be started from 8 to 13 years, during the pubertal phase, especially in females at risk of ovarian failure. Cryopreservation of oocytes or ovarian tissue before HSCT should be carried out 52 in selected patients, in particular in those with a lower probability of neoplastic ovarian infiltration.
Alkylating agents and RT are the main risk factors for damage of the sperm-producing germ cells and consequently for infertility. Unlike females, the cells that produce testosterone are more resistant to radiation. Azoospermia occurs after radiation doses of more than 1.2 Gy, whereas Leydig cells are damaged after radiation doses of more than 20 Gy in pre-pubertal patients and of more than 30 Gy in post-pubertal males. 53 Persistently, elevated follicle-stimulating hormone levels and normal levels of testosterone 2 are observed in males treated with TBI. Unlike with TBI, males who receive BU/CY or CY alone can recover testicular function in 17 and 61% of cases, respectively. 16 Age and pubertal status of males at the time of chemotherapy or RT do not have any impact on testicular dysfunction.
Pre-transplant testicular function assessment should include pituitary gonadotropin and testosterone levels, and it should be carried out starting from the pubertal phase (from 9 to 14 years) and then done regularly after this period. Sperm banking is the only method for preserving fertility in male adolescents undergoing potentially sterilizing therapies. 16 These procedures may be performed at diagnosis, during first-line therapy or before HSCT, although there are different results on spermatogenesis. 54 Moreover, it has been reported 55 that sperm cryopreservation encourages young patients with cancer, even if this procedure does not eliminate their fear of infertility.
Risk factors for hepatic toxicity
Acute and chronic GVHD, veno-occlusive disease, reactivation of viral hepatitis, iron overload as a consequence of multiple transfusions, chronic hepatitis and opportunistic infections are the most frequent acute or chronic liver diseases occurring after HSCT. Most frequent risk factors for veno-occlusive disease are reported in Table 2 .
Complete baseline pre-transplant evaluation of liver function including transaminases, cholestatic parameters, coagulation profile and ferritin levels is always recommended before transplant, and furthermore, hepatic Doppler ultrasound should be performed on patients at risk of veno-occlusive disease. Hepatitis B virus (HBV) carrier children given HSCT are at risk of developing HBV reactivation. This complication may also occur in children with resolved infection (HBsAg negative, anti-HBs positive and anti-HBc positive). Children given HSCT should be screened and monitored by complete HBV marker evaluation before and after HSCT, whereas the search for HBV-DNA should be carried out on patients coming from high-risk countries. 20 Hepatitis B virus carriers should be carefully monitored after transplant, especially after discontinuing immunosuppressive drugs.
Hepatitis B virus-naı¨ve patients, including the donors, should be vaccinated against HBV as soon as possible. 63 Preemptive therapy with lamivudine is also recommended in paediatric HBV carriers to decrease the chance of developing severe hepatic complications. 20 Risk factors for bone toxicity Prolonged therapy with corticosteroids or methotrexate or RT to weight-bearing bones represents risk factors for osteoporosis, mainly in female patients who have low levels of sex steroid hormone secretion or growth hormone deficiency or high levels of thyroid hormone, and/or prolonged periods of inactivity. A bone density scan is recommended for these patients when they enter long-term follow-up. However, bone density scan is not strictly necessary in all patients before HSCT.
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Older age at HSCT, acute and cGVHD, type of underlying disease (such as severe aplastic anaemia or ALL) and TBI are the main risk factors for avascular necrosis. 23, 24, 64 Univariate analysis alone showed that the continuous use of steroids after HSCT is a significant risk factor for avascular necrosis. 64 Pre-transplant screening for avascular necrosis by magnetic resonance imaging 52 is not recommended except in patients who have suspicious clinical signs for this complication, such as persistent bone pain.
Risk factors for late nephrotoxicity
Risk factors for chronic renal impairment in children undergoing HSCT include the underlying disease, surgery, chemotherapy, RT, immunotherapy and supportive treatments. Pre-transplant administration of nephrotoxic agents, such as cisplatin, ifosfamide (460-80 g/m 2 ), carboplatin or RT may induce the development of glomerular or tubular chronic renal failure. 65 TBI represents the main cause of renal failure following HSCT, likely by limiting compensatory hyperperfusion and thus resulting in a drop in glomerular filtration rate. 66 Pre-HSCT serum creatinine levels may be a predictive factor. 67 Pre-transplant assessment of renal function is recommended in all patients undergoing HSCT, and should include serum creatinine, albumin and protein evaluation and blood pressure measurement. Patients treated with nephrotoxic drugs should undergo evaluation of tubular and glomerular function including testing of 24-h urine concentrations of sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose and creatinine before HSCT.
Risk features for late neurological toxicity
Progressive leukoencephalopathy is the most devastating late neurological toxicity, occurring in patients who receive brain RT and/or intrathecal chemotherapy before HSCT and post-transplant intrathecal methotrexate. 28, 29 Performing a brain magnetic resonance imaging before HSCT represents the best diagnostic method to evaluate RT/CTinduced neurological toxicity. The images may vary depending on the amount of time from RT: that is, acute (1-6 weeks), with transient high-intensity white matter changes; early delayed (within 2-3 months), with transient diffuse or focal changes in deep and periventricular white matter, grey nuclei and brainstem; or delayed/late (after months or years), with leukoencephalopathy, mineralizing microangiopathy, necrotizing leukoencephalopathy or brain atrophy (diffuse sequelae). 28 Younger age at HSCT and cumulative dose of radiation may influence the neuropsychological development of children. In particular, children who receive cranial RT before 3 years of age seem to have a higher risk of neurological sequelae. 68 Therefore, administering TBI in the CR is preferable above 3 years of age.
Risk features for hearing toxicity
Cisplatin or high doses of carboplatin, CY, TT, as well as high doses of radiation (30 Gy or higher) to the head or brain, and surgery involving the brain, ear or auditory nerve, and certain antibiotics and diuretics may cause hearing loss. 32 Gurney et al. 30 reported a 2% frequency of hearing loss among the survivors of a cohort of individuals treated with HSCT during childhood or adolescence. Furthermore, they observed that platinum compounds, particularly cisplatin, are implicated in auditory impairment. Younger age and higher cumulative dose of cisplatin seem to be associated with greater severity of hearing damage. 69 We recommend that patients who receive ototoxic treatment should undergo expert audiologic paediatric evaluation before HSCT.
Risk features for dental defects Treatment with CT before permanent teeth are fully formed, as well as RT involving the mouth and/or salivary glands are the main risk factors for dental defects after cancer treatment in childhood. 32 These defects may include hypoplasia, root anomalies, tooth dwarfism, incomplete calcification, agenesis and so on. Moreover, xerostomia, which is a common finding in patients with cGVHD, can predispose to oral complications. 70 An oral/dental examination is recommended before HSCT, especially for patients who are candidates for allogeneic HSCT, as the risk of oral cancer may be increased.
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Conclusions
Pre-transplant assessment includes any subjective or objective evaluation that may help in defining the baseline conditions of the patient and identifying the main comorbidities that could increase transplant-related toxicity. Collecting the patient's clinical history and identifying pre-transplant and post-transplant risk factors would allow to tailor pre-HSCT evaluation and HSCT procedures.
Several studies of adults analysed single organ comorbidities as predictors of transplant outcome. Different grading systems have been used to assign patients to different strategies. Sorror et al. 71 evaluated the impact of pre-HSCT factors as assessed by the Charlson Comorbidity Index on transplant outcome. The scores were weighted from 1 to 6 and the total scores were divided into four categories as prognostic factors for mortality. The authors evaluated transplant-related toxicity using the Common Toxicity Criteria version 2.0 of the National Cancer Institute, which contains toxicity categories and several adverse events graded as: 0 (none), I (mild), II (moderate), III (severe), IV (life-threatening or debilitating) and V (death). Alamo et al. 72 reported performance status based on the Karnofsky or Zubrod scales as surrogates of comorbidity markers.
Acute and chronic toxicity in the paediatric age is usually graded using the WHO score, whereas Karnofsky or Lansky scales are used for performance status. The Common Terminology Criteria for Adverse Events V3.0 (CTCA) of the National Cancer Institute is a recently published (2006), and describes terminology containing several categories. Each category is a broad classification of adverse events based on anatomy and/or pathophysiology, and is accompanied by descriptions of severity (grade). The Common Terminology Criteria for Adverse Events V3.0 is available on line in http://ctep.cancer.gov/reporting/ ctc.html. 73 These guidelines could be useful before HSCT to assess pre-transplant comorbidities even in paediatric patients.
Reduced intensity CRs (RICs) are increasingly being used for adult cancer patients in whom the frequency of comorbidities is high; in children, RICs are successfully used in a variety of nonmalignant diseases. However, specific data on RICs in children with refractory leukaemia are not currently available. 74 The most common indications for RIC in children include Fanconi anaemia, severe aplastic anaemia and severe combined immunodeficiency. Del Toro et al. 75 reported that grades 3 or 4 nonhaematologic toxicity and several severe infections were observed in 21 children who had been transplanted for malignant and nonmalignant disease. However, they concluded that RICs are also feasible and tolerable in children, with 85% of recipients achieving 50% donor chimerism. Several reports have demonstrated that RIC can be a promising transplant option for children and adolescents, especially for those with malignancies that are not too advanced, as the graft vs malignancy effect seems to be too slow to overcome a high-risk progressive malignancy. Therefore, RICs should be taken into consideration for paediatric patients whose condition at the time of transplantation places them at high risk of toxicity (comorbidities) from myeloablative transplantation.
Prospective studies are needed to standardize the eligibility criteria for different types of CRs to decrease transplant-related morbidity and to increase the antitumor effect in cancer patients.
